Novo Nordisk is trading 3.62% down at €36.21 after closing at €37.57 on September 18, amid company-specific pressure as investors focus on its Capital Markets Day in London.
- There is no confirmed September 21 catalyst; the broader market is rising, so general risk sentiment does not explain the decline.
- Morgan Stanley’s downgrade, semaglutide patent-cliff concerns and skepticism about medium-term growth have added pressure.
- Management is expected to outline strategy, pipeline priorities and performance plans.